Background Systemic sclerosis is a chronic systemic disease of unknown etiology. There are a number of autoantibodies that correlated with disease severity and severity of skin involvement (1). Various studies have shown that AntiCCP Ab can also be seen in other autoimmune diseases such as systemic sclerosis (2–4). Results Polimen et al (4) and Morita et al (3) studies showed no relationship was found between AntiCCP Ab with skin Rodnon score.
Objectives This study aimed to determine the relationship between serum levels of AntiCCP Ab with severity of skin involvement in systemic sclerosis patients referred to Tohid Hospital.
Methods This study is a cross - sectional study, in the study population included all patients diagnosed with systemic sclerosis according to ACR 1980 criteria and subtypes according to Le Roy, that between 2013 and 2014 referred to Tohid hospital. We used from MRSS index to determine the extent of skin involvement. Sampling was available and we used to determine this association from chi-square statistics and to determine the amount of the connection from Phi statistics. Serum antibodies directed against CCP were assessed by ELISA.
Results The results showed that the patients who were evaluated at the end of study were 50 patients, of whom 48 were women (96%) and (2%) 2 were male. The mean age of subjects is 38±10 years. The subtype of systemic sclerosis in 15 (%30 percent) of the patients were diffuse systemic sclerosis and 35 patients (%70 percent) have limited systemic sclerosis. Serum Anti CCP Abntibody was positive in 10% (5 patients). Also, there is no statistically significant relationship between the severity of skin involvement with Anticcp Ab (p=0.164).Severity of skin involvement in both groups was more severe form, and there is no statistically significant relationship between the severity of skin involvement and subtypes of systemic sclerosis (p=0.233). Also we didn't find no association between levels AntiCCP and joint symptoms and other symptoms.
Conclusions In this study wasn't observed a significant correlation between serum levels of Anti CCP Antibody with severity of skin involvement in patients with systemic sclerosis (p=0.164),also serum level of AntiCCP Antibody couldn't as a predict factor to determine the severity of the disease. It seems that the relationship between other symptoms of systemic sclerosis and serum level of AntiCCP Antibody may be result from overlapping with RA.
Shand L, Lunt M, Nihtianovas, Hoseini M, Silman A, Blake M “Relationship between Change in skine score and disease outcome in diffuse cutaneous scleroderma” arthritis rheum 2007 jul:56(7):2422–31.
Marrone M, Chiala A, Tampoia M, Iannone F et al, Prevalence of anti-CCP antibodies in systemic sclerosis, Reumatismo. 2007 Jan-Mar;59(1):20–4.
Morita Y, Moro Y, Sugiura K, Tomita Y “Anti cyclic citrollinated Peptide in Systemic Sclerosis”. 2008 jul:26(4):542–7.
Polimeni M, Feniman D, Skare Ts, Nishihara Km “Anti cyclic citrollinated Peptide antibodies in scleroderma patints”.clin rheumatal 2012 may;31(5):877–80.
Disclosure of Interest None declared